Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 3 1Phase 1 1

Status

Terminated 6Active not recruiting 4Unknown 3Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 6

Conditions

Ovarian Neoplasms 5Carcinoma, Ovarian Epithelial 3

Interventions

Paclitaxel 69Carboplatin 66Cisplatin 36pembrolizumab 34Gemcitabine 24liposomal doxorubicin 23Cyclophosphamide 23Topotecan 22Bevacizumab 20Taxes 14Docetaxel 13niraparib 12Nivolumab 12olaparib 10fludarabine 10Doxorubicin 9Surveys and Questionnaires 8Radiotherapy 8Oxaliplatin 8aldesleukin 7Filgrastim 7rucaparib 6oregovomab 6fludarabine phosphate 6durvalumab 6avelumab 6Interleukin-2 6Hyperthermic Intraperitoneal Chemotherapy 6Fluorodeoxyglucose F18 6Cytoreduction Surgical Procedures 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Terminated × oregovomab × Gynecologic × Clear all
NCT03100006 2022-06-13

ORION-01

National Cancer Centre, Singapore

Phase 1/2 Terminated
13 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

NCT03162562 2020-12-22

The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer

CanariaBio Inc.

Phase 1 Terminated
10 enrolled
Gynecologic

Ovarian Neoplasms

NCT00034138 2007-12-18

A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma

Unither Pharmaceuticals

Phase 1/2 Terminated
24 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00034372 2007-12-18

Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma

Unither Pharmaceuticals

Phase 2 Terminated
102 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00050375 2007-12-18

Clinical Trial for Ovarian Cancer (OvaRex®)

Unither Pharmaceuticals

Phase 3 Terminated
354 enrolled
Gynecologic

Ovarian Neoplasms

NCT00086632 2007-12-18

Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment

Unither Pharmaceuticals

Phase 2 Terminated
40 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡